Form 4: ResMed Director Jan De Witte Sells 2,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Jan De Witte of ResMed Inc. sold 2,000 shares of company stock at $243.47 per share under a pre-arranged 10b5-1 trading plan.
Summary
- On May 20, 2025, Jan De Witte, a director of ResMed Inc., sold 2,000 shares of ResMed common stock.
- The sale was executed at a price of $243.47 per share.
- The transaction was conducted under a Rule 10b5-1 plan adopted on February 3, 2025.
- Following the transaction, De Witte directly owns 5,806 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 plan suggests the director is selling shares according to a pre-arranged schedule to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of adoption of Rule 10b5-1 plan |
| 05/20/2025 | Date of transaction (stock sale) |
| 05/21/2025 | Date of signature on the Form 4 filing |
Keywords
ResMed, Jan De Witte, Form 4, Stock Sale, Director, RMD, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.